Introduction {#ene13775-sec-0005}
============

Fabry disease, a panethnic X‐linked lysosomal disease, is characterized by accumulation of glycosphingolipids, mainly globotriaosylceramide and its deacylated form globotriaosylsphingosine (Lyso‐Gb3), in many types of cells [1](#ene13775-bib-0001){ref-type="ref"}, [2](#ene13775-bib-0002){ref-type="ref"}. Although enzyme‐based screening has been implemented for Fabry disease, it may fail to detect up to one‐third of heterozygous females [2](#ene13775-bib-0002){ref-type="ref"}. Recently, genetic screening has been developed for the high‐risk population in both male and female patients [3](#ene13775-bib-0003){ref-type="ref"}. A Sequenom iPLEX assay has been designed and validated to identify α‐galactosidase A (*GLA*) gene mutations and variants with 100% accuracy and sensitivity in Taiwan [4](#ene13775-bib-0004){ref-type="ref"}.

The aim of the present study was to apply the Sequenom iPLEX assay to screen 26 hotspot mutations and variants of *GLA*, which are involved in Taiwanese Fabry disease, in a cohort of young stroke patients.

Methods and materials {#ene13775-sec-0006}
=====================

The Stroke Registry in Chang Gung Healthcare System in Taiwan [5](#ene13775-bib-0005){ref-type="ref"} has established a blood sample bank collecting important DNA. The study protocol was in compliance with the Helsinki Declaration and approved by the institutional review board of Linkou Chang Gung Memorial Hospital.

Young stroke patients were aged 18--55 years and included 488 males and 173 females with ischaemic stroke \[17 males and four females with transient ischaemic attack (TIA)\] and 272 males and 67 females with hypertensive intracerebral hemorrhage (HICH). Informed consent for the genetic analysis was obtained from all recruited patients.

Ischaemic stroke subtypes were classified according to our previous study [6](#ene13775-bib-0006){ref-type="ref"}. Hypertension‐related HICH was considered when the hematoma was located in the basal ganglion (putamen, thalamus), cerebellum and pons. The definitions of vascular risk factors and clinical survey for young stroke were mentioned in our previous study [6](#ene13775-bib-0006){ref-type="ref"}.

The 26 Fabry disease *GLA* mutations and their protein nomenclature are listed in Table [S1](#ene13775-sup-0001){ref-type="supplementary-material"}. These mutations/variants included 21 *GLA* mutation single‐nucleotide polymorphisms reported in Taiwan [4](#ene13775-bib-0004){ref-type="ref"} and five *GLA* benign variants previously detected in patients with stroke [4](#ene13775-bib-0004){ref-type="ref"}. The protocol of MassARRAY‐based mutation genotyping using the assay Designer v.4.0 software (Agena Bioscience, San Diego, CA, USA) is mentioned after Table [S1](#ene13775-sup-0001){ref-type="supplementary-material"}. A leukocyte *GLA* activity assay was determined according to the previous method [1](#ene13775-bib-0001){ref-type="ref"}. The diagnosis of Fabry disease was based on a leukocyte *GLA* activity \<4.76 nmol/mg protein/h.

Results {#ene13775-sec-0007}
=======

The clinical features of the young stroke patients are presented in Table [S2](#ene13775-sup-0001){ref-type="supplementary-material"}. Two males with stroke onset at 49 and 50 years, respectively, were detected. Both had an intronic *GLA* mutation of IVS4+919G\>A, and their *GLA* enzyme activity was 3.77 and 7.15 nmol/mg protein/h, respectively.

No Fabry disease was found in patients with TIA or HICH, and also none in female patients. The frequency of Fabry disease in our cohort was 0.2% for all stroke patients with 0.3% for ischaemic stroke and 0% for HICH.

Discussion {#ene13775-sec-0008}
==========

The present study used a Sequenom iPLEX assay as the first‐line determination of *GLA* mutation, further confirmed with plasma *GLA* enzyme activity assay. The Sequenom iPLEX assay with nation‐specific hotspot mutation genes is suggested as a cost‐effective screening method for large series.

In the review of stroke screening (Tables [1](#ene13775-tbl-0001){ref-type="table"} and [S3](#ene13775-sup-0001){ref-type="supplementary-material"}), the overall frequency was 0.62% in 2420 Asian strokes with 0.63% in male subjects, 0.58% in female subjects, 0.72% in 2081 ischaemic strokes and 0% in 339 hemorrhagic strokes. The overall frequency was 0.88% in 10 405 non‐Asian strokes with 0.77% in males and 1.08% in females. There were 9431 ischaemic strokes with 1586 cryptogenic strokes, 571 hemorrhagic strokes and 403 others. The frequency of Fabry disease was 0.83% in ischaemic stroke with 2.27% in cryptogenic stroke and 1.40% in hemorrhagic stroke.

###### 

The frequency of Fabry disease in young stroke screening in Asian and non‐Asian countries

  Country     Age      Stroke subtype                                                                    Number of patients                   \% mutation in gender                                         \% mutation in stroke subtype
  ----------- -------- --------------------------------------------------------------------------------- ------------------------------------ ------------------------------------------------------------- ------------------------------------------------------------------------------
  Asia        18--91   IS (CI + TIA) 2081, HS 339                                                        2420 (1902 males + 518 females)      Total 0.62% \[12 males (0.63%), and three females (0.58%)\]   IS (CI + TIA) 15 (0.72%), HS 0%
  Non‐Asian   15--70   IS (CI + TIA) 9431 including cryptogenic IS (CI + TIA) 1586, HS 571, others 403   10 405 (6512 males + 3893 females)   Total 0.88% \[50 males (0.77%), 42 females (1.08%)\]          IS (CI + TIA) 78 (0.83%), cryptogenic IS (CI + TIA) 36 (2.27%), HS 8 (1.40%)

CI, cerebral infarction; HS, hemorrhagic stroke; IS, ischaemic stroke; TIA, transient ischaemic attack.
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The incidence of late‐onset IVS4+919G\>A mutation is reported as 1:1600 in Taiwanese newborns [7](#ene13775-bib-0007){ref-type="ref"}. Patients carrying IVS4+919G\>A and classical Fabry mutations could be distinguished from healthy controls by an elevated plasma lyso‐Gb3 [8](#ene13775-bib-0008){ref-type="ref"}. Although similar magnetic resonance imaging findings for both classical Fabry disease and the subtype with IVS4+919G\>A mutation [9](#ene13775-bib-0009){ref-type="ref"}, patients with IVS4+919G\>A have a higher frequency of deep white matter hyperintensities and a higher incidence of infarctions and pulvinar signs than healthy controls [7](#ene13775-bib-0007){ref-type="ref"}. Lyso‐Gb3 also correlated with age and left ventricular mass index in Fabry patients with IVS4+919G\>A mutation [8](#ene13775-bib-0008){ref-type="ref"}.

Our study has two limitations: (i) the Sequenom iPLEX assay cannot cover the full range of Fabry mutations since Fabry disease has more than 800 mutations affecting both males and females; (ii) measurement of lyso‐Gb3, a plasmatic biomarker of Fabry disease, was not performed.

Conclusion {#ene13775-sec-0009}
==========

IVS4+919G\>A mutation gene can be seen only in Taiwanese newborn and young ischaemic stroke patients and is rarely detected in other Asian and non‐Asian countries. There is less gender difference in Caucasians, but few Fabry disease occurrences are found in female Asians.
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